ClinicalTrials.gg
Drug

Guselkumab clinical trials

Also written CNTO1959 and Tremfya.

studies test it
80
open now
18
in phase 3
31
first study started
2011

How each study uses guselkumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the guselkumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
13 Jul 2017 · TREMFYA · BLA 761061 (FDA, Drugs@FDA)
European Union
10 Nov 2017 · Tremfya · EMEA/H/C/004271 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Guselkumab
60
Guselkumab Dose 1
8
Guselkumab Dose 2
7
Guselkumab Dose 3
5
Guselkumab 100 mg
2

Brand

Tremfya
25

Development codes

CNTO1959
30

Studies by the year they started

80 studies that test it; most in 2021 (10)

Studies that test guselkumab, by start year
YearStudies
20112
20121
20132
20142
20155
20161
20174
20187
20198
20207
202110
20228
20235
20247
20256
20265

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
13
Phase 2
18
Phase 3
31
Phase 4
15
No phase
4

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 60 · Other 20

Janssen Research & Development, LLC (40) · Janssen Pharmaceutical K.K. (8) · Janssen-Cilag Ltd. (4) · University of California, San Francisco (3) · Oregon Health and Science University (2) · University of California, San Diego (2) · NYU Langone Health (2) · Second Affiliated Hospital, School of Medicine, Zhejiang University (2)

Often tested with

Tested in the same studies.

Ustekinumab (7) · Ixekizumab (6) · Secukinumab (5) · Risankizumab (5) · Methotrexate (4) · Adalimumab (4) · Golimumab (3) · Bimekizumab (3)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 14, 4 in phase 3

Studies that test guselkumab, phase 3 first.

Studies

Open first, then newest update. How each study uses guselkumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 80

See all 80 studies that test guselkumab →

Given beside what is tested · 7 — guselkumab is usual care or a partner of the new treatment
As the comparator · 2 — what is tested is compared with guselkumab

Codes

What other systems call guselkumab · ClinicalTrials.gg INT000013

  • MeSH (NLM) C000588857guselkumabConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 089658A12DGUSELKUMABConfirmed FDA, NLM, Wikidata
  • RxNorm 1928588Confirmed FDA, Wikidata
  • Wikidata Q15708315guselkumabConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C150390GuselkumabOne source FDA
  • DrugBank DB11834One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.